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CHAPTER 1
INTRODUCTION
1.1 FAM129B
FAM129B, also known as MINERVA or Niban-like Protein 1, is part of a small
family of proteins that includes FAM129A and FAM129C. Little is known about the
structure and functions of these proteins except that all 3 proteins have been
implicated in cancer. FAM129A has been reported to be expressed in different types
of cancer and is shown to be involved in cancer cell proliferation[1]. FAM129C has
been shown to be highly expressed in patients with chronic lymphocytic leukemia
(CLL)[2]. A proteomics study in 2009 by Old et al. was the first paper to mention
FAM129B. In this study FAM129B was shown to be highly expressed in melanoma
cells, an invasive skin cancer cell line, andimplicated in cancer cell invasion[3].
In the subsequent years after the Old et al study, FAM129B was mentioned in a
modest number of publications. In 2011, a study published in our lab reported that
FAM129B is associated with the adherent junctions in confluent HeLa cells and
suppressed the TNFα apoptotic pathway[4]. In 2012, a study by Takahashi et al
showed that knockdown of FAM129B in mice delayed wound healing compared to
controls [5]. This observation corroborates the notion that FAM129B is involved in
cancer cell invasion since both processes rely on increased cell mobility, In 2014, a
study showed that FAM129B plays a role in the wnt/β-catenin pathway, a pathway
well-known to be upregulated in cancer cells[6]. The study, also showed that
knockdown of FAM129B promotes apoptosis in melanoma cells, a strikingly different
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observation than what was observed in our lab. Finally, in January 2016, a study
showed that FAM129B is has a tyrosine phosphorylation site (Y593). This tyrosine
is phosphorylated by the epidermal growth factor receptor (EGFR). Phosphorylation
of FAM129B at this site promotes the binding of FAM129B to H-ras and K-ras,
which in turn, promotes glycolysis – part of the Warburg effect in cancer[7].
1.2 Domain Structure of FAM129B.
FAM129B, according the NCBI databases, exists in two isoforms in Homo
Sapiens. Isoform 1 which is made up of 746 amino acids and isoform 2 which is
made up of 733 residues. Both isoform are completely identical in conserved
domains and phosphorylation sites with the exception that isoform 1 has an
additional 13 amino acid at the amino terminus.
At the amino terminus, FAM129B has a Pleckstrin Homology (PH) domain. This
domain has been shown to interact with phospho-lipids at the membrane and is
involved in many signaling cascades[8]. This domain also could explain why
FAM129B is associated with the Adherent Junctions. At the carboxyl end of
FAM129B , there is a tyrosine phosphorylation site (Y593) and a proline rich domain
that has six serine phosphorylation sites ( ser628 , ser633, ser652, ser668, ser679,
ser683) . Four of the sites ( ser628, ser633, ser679, ser683) are phosphorylated
directly by MAP kinase , while the phosphorylation site for the other two serines
remains unknown. Old et al has shown that treatment of melanoma cells with MEK
inhibitors relocates FAM129B to the plasma membrane[3]. This observation implies
that phosphorylation of FAM129B by MAP kinase regulates FAM129B localization.
FAM129B has a DLG and ETGE motif upstream of the proline rich domain. These
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domains are conserved in many different proteins, such as NRF2 (nuclear factor
protein 2), which is a basic leucine zipper transcription factor that regulates the
expression of anti-oxidant proteins that are activated when cells are exposed to
oxidative damage[9]. Another protein is IKKβ (Inhibitor of Nuclear Factor Kappa B
Kinase), which phosphorylates the regulatory domain of the protein NF-κB (nuclear
factor kappa B), and promotes the transactivation and translocation of NF-κB to the
nucleus and transcription of anti-apoptotic proteins and proteins involved in cell
proliferation[10]. The expression of both proteins is regulated by KEAP1 (Kelch-like
associated protein 1). KEAP1 binds to these proteins through its KELCH repeats to
the ETGE

domain of these proteins and targets them for degradation by the

proteasome[9]. The domain structure of FAM129B is further illustrated in Figure1.1

Figure 1.1: Domain Structure of FAM129B
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1.3 Apoptosis
Apoptosis is one type of programmed cell death (PCD). Other types of PCDs include
autophagy and programmed cell necrosis. Apoptosis is characterized by certain
biochemical and morphological traits. Morphological traits include cellular shrinkage,
membrane blebbing, and chromosome condensation. Apoptosis can be induced by a
loss of a positive signal, for example, lack of growth factors, or a receipt of a negative
signal, for instance, DNA damage or a death ligand. Apoptosis is a highly regulated
cellular process. Dysregulation in the apoptotic pathway is associated with many
diseases including cancer[11]. Weingburg and Hanahan characterized the suppression
of apoptosis as one of the major hall marks of cancer[12]. There are two distinctive
apoptotic pathways: the intrinsic or mitochondrial pathway and the extrinsic or death
ligand pathway[13].
In the intrinsic pathway(Figure 1.2), cytochrome C is released from the mitochondria
with the aid of some proteins from the bcl-2 family and form the apoptopsome with a
protein called Apaf-1. The apoptopsome is then used as a platform for activating the

Figure 1.2. Intrinsic or Mitochondrial Apoptotic pathway
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initiator caspase 9. Caspase 9 activates the executioner caspase 3 and then apoptosis
proceeds irreversibly[14].
The extrinsic pathway of apoptosis involves a death ligand docking to a death receptor.
There are many types of death ligand and receptors. Two of the most studied are Fasmediated apoptosis and TNFα mediated apoptosis. In the Fas mediated apoptosis
(Figure 1.3), the fas ligand binds to the Fas-receptor. This induces a conformational
change that enables the recruitment of FADD adaptor proteins, forming the DISC, the
death inducing signaling complex. Once the DISC is formed the initiator caspase 8 is
then recruited to the complex and activated. Caspase 8 then proceeds to activate the
executioner caspase 3 and apoptosis proceeds[15].

Figure 1.3: The Fas-mediated Apoptotic Pathway.
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The other well studied extrinsic apoptotic pathway is the TNFα pathway(Figure 1.4).
TNFα (tumor necrosis factor α), is a cytokine that binds to the TNF receptor. Once
bound to the receptor, it forms complex I which is bound to the membrane. Complex I
then dissociates from the membrane and the FADD adaptor proteins bind to the
complex along with other adaptor proteins. The enlarged complex now designated
complex II, forms the DISC, the platform for activating caspase 8. Caspase 8 then
activates other executioner caspases and apoptosis proceeds [11]. The TNFα pathway
also activates the NF-κB pathway. NF-κB (nuclear factor kappa B) is a transcription
factor that activates the transcription of proteins involved in proliferation and cell survival
including the IAP family of proteins which are reported to be inhibitors of apoptosis[16].
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Figure 1.4: The TNFα Apoptotic Pathway

Suppression of apoptosis is one of the hall marks of Cancer[12]. Many chemotherapies
involve using the death ligands to induce cancer cell death. Also, many anti-apoptotic
proteins have been used as drug targets. Small molecules targeting various
components of the apoptotic pathway have been already developed. Examples of these
molecules are: ABT-737 and ABT-263 have been reported to act on the BCL-2 family
proteins. AT-406 and HGS-1029 are thought to antagonize cIAPs[13]
1.4 Cancer and Metastasis
Cancer is a group of diseases where abnormal cellular growth and proliferation
occurs to form tumors which have the potential to spread and invade to other parts
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of the body. Over 100 types of cancers affect humans. As reported in 2010 by the
NCI (National Cancer Institute), 14.1 million cases occur globally. Cancer is the
cause of around 14.6% of human deaths. The most common types of cancer in
males are lung cancer and prostrate cancer while in females, the most common
types are breast and cervical cancer[17].
Weinberg and Hanahann published a review in 2011 that summarizes the
characteristics of cancer, which they named the cancer hallmarks. The cancer Hall
marks are[12]:
1. Sustaining Proliferative Growth
2. Evading Growth Suppressors
3. Activating Invasion and Metastasis
4. Enabling Replicative Immortality
5. Inducing Angiogenesis
6. Resisting Cell Death
Metastasis is the process where the primary tumor undergoes genetic and
biochemical changes that cause the tumor to detach from the primary site and form
colonies at a secondary site[18]. Metastasis are very common at later stages of
cancer – 90 % of cancer deaths are due to metastatic tumors[17]. The spread of
metastatic tumors can occur via both the blood stream and the lymph nodes. The
most common site of metastasis are lung, liver, brain, and the bones. For the
metastatic spread to occur, primary site tumors induce angiogenesis, which is the
process of blood vessel formation. The malignant cell then breaks away from the
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primary tumor by degrading the proteins that attach it to the extracellular matrix
(ECM) such as cadherins. The malignant cells then enter the blood stream and
circulates the bloodstream until they adhere to the blood vessel wall and exit the
blood stream and form the colony at a secondary site[19]. The location for
metastases is not random since different types of cancer tend to spread to particular
and specific organs. An example is breast cancer. Breast cancer primary tumors
tend to choose lungs and bones as their metastatic site[20]. This specificity is
mediated by signaling molecules such as cytokine or chemokines and TGFβ
(transforming growth factor beta)[21].
Cellular processes that promote cell motility seem to be mostly upregulated in
cancer cell metastasis. One example is the Epithelial to Mesenchymal Transition.
EMT is critical to morphogenesis and homeostasis of solid tissues. In cancer,
malignant epithelial cells undergoing EMT acquire properties that facilitate
metastatic spread. EMT renders cancer cells resistant to different types of therapies,
often by reducing apoptotic sensitivity. One of the proteins that is down-regulated
during EMT is E-Cadherin and the Adherent Junctions are one of mostly altered
proteins in Invasive tumors[18].
1.3 Significance and Aims
Cancer is the second leading cause of death in United States. Most of the deaths that
occur in cancer are due to metastatic tumors which happen at the later stages of the
disease and are resistant to most cancer therapies[17]. Therefore, developing new
therapies for cancer is essential. FAM129B suppresses apoptosis and promotes cell
mobility. Also, FAM129B is highly expressed in tumor cells. Thus, studying the structure

10

and function of FAM129B will help in understanding one of the mechanisms by which
cancer cells evade death and metastesize, which will lead to life-saving advances in
cancer treatment. Furthermore, FAM129B could be a potential drug target for some
types of cancer since the loss of FAM129B in cancer cells sensitizes cells to apoptosis
and inhibits invasion, which will aid in the development of new cancer therapies and
most importantly treatments for metastatic cancers.
Cancer progression is a highly complex mechanism that has yet to be
understood,despite decades of research. In our proposed research, we show that
FAM129B is involved in cancer cell progression. It suppresses apoptosis and promotes
metastasis. Thus, knowing more about FAM129B and its function will give an insight
into the mechanisms cancer cells utilize to progress. This will lead to new research
approaches and more developments in cancer research and understanding the
complicated mechanisms involved in cancer. Therefore, my aims addressed in this
thesis are
1. Structural Characterization of FAM129B
2. Characterizing the interaction between FAM129B and KEAP1
3. The role of FAM129B in cancer cell invasion and metastasis
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CHAPTER 2
MATERIALS AND METHODS
2.1 Vectors used in this Study
All vectors in this study were cloned in our lab. FAM129B was cloned into T7 Sumo
Expresso vector which has a Histidine tag and Sumo tag at the amino-terminus
(Lucigen). This clone was used to express FAM129B in E. coli and purify recombinant
FAM129B. FAM129B was also cloned into a pEFGP-n3 vector, which has GFP (Green
fluorescent Protein) tag at the carboxyl terminus of the protein . This clone was used to
express FAM129B in mammalian cell culture. KEAP1 was cloned into a pDEST15
vector which incorporates a GST tag at the amino-terminus of the protein. This clone
was made to express KEAP1 in E. .coli and to purify the protein
2.2 PCR and Cloning
Invitrogen Gateway Technology was used to clone KEAP1 into pDest15 . Gateway
Technology is a highly efficient and fast way to clone genes into multiple expressing
systems for functional studies and protein expression. The target gene is first cloned
into an Entry vector. The insert of the ENTRY clone can then be recombined efficiently
to a destination vector by a ligation reaction. The target gene was amplified by PCR and
cloned in a pENTR SD-TOPO vector according to the manufacturer’s protocol. The
vector was then transformed into TOP10 competent cells and plated on LB agar plates
using kanamycin as a selection marker. The vectors were then purified using the Quick
plamid mini-prep kit from Invitrogen. The insert in the Entry clone was recombined with
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the destination vector according to the manufacturer’s protocol. The final vector was
checked for the fidelity of the insert via sequencing (Gensript, Piscataway, NJ)
2.3 Agarose Gel Electrophoresis
The HOEFER mini DNA electrophoresis apparatus was used for DNA samples.
0.8% or 1% agarose was made in 1xTAE buffer (40mM Tris base, 0.1% acetic acid,
1mM EDTA, pH 8.0) . The agarose was dissolved in the buffer by heating the solution
in the microwave at 30 second increments until the agarose was completely dissolved.
The agarose was cooled down and 3 ul of Ethidium Bromide was added. The agarose
solution was then poured into a gel casting tray and a 1.5mm 10-well comb was
inserted to form the loading wells.

The gel was then allowed to solidify at room

temperature and placed in the apparatus filled with TAE buffer. Samples were prepared
by mixing 5 μl of DNA with 1 μL of 6x loading buffer (Catalog# B7021S, New England
Biolabs). The samples were loaded into the wells, along with a DNA standard, 1 Kb plus
or 100 bp ladder from New Englands Biolabs. The agarose gels were run at 90-100V
until the bromophenol blue dye ran approximately 3/4 of the length of the gel. The DNA
fragments were then viewed and photographed using a UV-transilluminator.

2.4 Cell culture
HEK293, HeLa, and A549 cells were used in the course of this study. HEK293 is a
human embryonic kidney cell line that is widely used for transient transfection studies
due to its high transfection efficiency. This cell line was maintained in DMEM media
supplemented with 10 % fetal bovine serum (FBS).
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HeLa cells are a cervical cancer line. This cell line is the most used cell line in world
research due to its robustness and ease of culture. HeLa cells are used for apoptosis
studies and immunofluorescent microscopy. HeLa cells were maintained in DMEM
media with 10% FBS
A549 cells are a type of lung cancer line. They are epithelial cells. This cell line is
widely used to study epithelial to mesenchymal Transition (EMT). This cell line was
maintained in RPMI 1640 media supplemented with 10 mM L-glutamine and 10 % FBS.
All cells were maintained in T75 flasks at 37oC with 5% CO2 in a humidified
environment. The media (10 mL) was changed every other day.
Cells were sub-cultured at 80-90% confluency. The media was aspirated and cells
were washed once with Phosphate Buffered Saline (PBS). The cells were then
incubated with 4 ml of 0.25% Trypsin-EDTA (Invitrogen) until the cells detached from
the bottom of the culture flask. The cell suspension was then transferred to a 15 ml
sterile tube and 4 ml of Complete media was added to inhibit Trypsin activity. Cells were
pelleted by centrifugation at 2000g for 10 min. The media was then carefully removed
and the cells were resuspended with 4 ml of complete media. The cells were then
seeded in either 6-well plates, 60 mm dishes ,or 100 mm dishes for experimental
purposes. For experiments that required accurate cell counts , the cells were counted
using a hemocytometer, and the appropriate number of cells were seeded in the
experimental flask.
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2.5 Freezing and Thawing culture cells
Cells grown to 80-90% confluence in a 75 cm2 flask, were treated with 4 ml trypsin in
a 37 °C incubator. 4 ml growth medium with 10 % FBS were then added to inhibit
trypsin activity. The mixture was transferred to a 15 ml sterile tube and centrifuged at
2000g for 10 min at room temperature to pellet the cells. The cell pellet was resuspended in 2 ml freezing medium (complete) growth medium with 10% (v/v) DMSO.
Aliquots of 1 ml (3x10⁶ cells) were placed in foam boxes at -80°C overnight and then
immersed in liquid nitrogen the next day . Cells were recovered from the nitrogen tank
by rapid thawing in a 37°C water bath, and then immediately re-suspended in the
appropriate culture medium and transferred to a 75 cm 2 tissue culture flask.
2.6 Soluble protein fractions
Cells grown in plates were washed with PBS (Invitrogen) supplemented with 0.2
mM PMSF (Sigma) and then lysis buffer (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1%
Triton X-100, 10% glycerol, 0.2 mM PMSF) supplemented with a 1X cocktail of
phosphatase and protease inhibitors (Sigma) was added and the cells were incubated
on ice for 20 minutes. The cells were then scraped and the sample was collected into a
pre-chilled microfuge tube. The cells were vortexed at maximum speed for one minute
and the tubes were rotated in the cold for 20 min. The cell lysate was centrifuged for 15
min at maximum speed. The supernatant was designated the soluble fraction.

2.7 Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE)
. The Novex Secure Lock cell from Invitrogen was used for Resolving SDSPAGE gels. Running gels consisted of a 12 % separating gel and 4% stacking gel. The
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electrophoresis buffer contained 0.192 M glycine, 0.025 M Tris-HCl, pH 8.3 and 0.1%
SDS. Proteins (1-5 ug) or protein samples (25-100 ug ) were heated for 5-10 min at
70oC in 1 X SDS sample buffer with 20% 2-Mercaptoethanol . The electrophoresis was
carried out at a constant voltage of 140 V until the dye front reached the bottom of the .
gel. The gel was then either subjected to a western blot or stained in 0.05% Coomassie
Brilliant Blue R reagent in 45% (v/v) methanol, 9% (v/v) acetic acid in distilled water for
15-30 min, and de-stained in 30% (v/v) methanol, 7.5% (v/v) acetic acid in distilled
water.
2.8 Western blotting
Samples were resolved by SDS-PAGE. The gel was then transferred to 0.45 µm poresize nitrocellulose membrane (Bio-Rad) using a HOEFER transfer apparatus. The filter
blotting paper (BioRad) and the nitrocellulose membrane (BioRad) were soaked in
transfer buffer. A sandwich was then assembled (foam sponge, filter paper, gel,
nitrocellulose membrane-filter paper, foam sponge) making sure to exclude any air
bubbles. The sandwich was placed in a transfer tank filled to the required mark with
transfer buffer (0.192 M glycine, 0.025 M Tris-HCl, pH 8.3), with the nitrocellulose
membrane facing the negative electrode. The transfer was run at a constant current of
400 mA for 90-120 min. The membrane was blocked using a 5% milk solution in 1x
TBST (10mM Tris, pH 7.4, 150mM NaCl, 0.1% Tween 20) at room temperature for one
hour. The membrane was washed with TBST 3 times and incubated with primary
antibody diluted with 5 % BSA with TBST or 5 % milk with TBST. Incubation was carried
with gentle shaking, overnight in the cold room. The membrane was then washed three
times with TBST at 5 min increments. It was then incubated with a secondary antibody
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coupled to Horseradish Peroxidase (HRP) diluted in TBST-milk for 1 hour at room
temperature with rocking . The membrane was then washed three time with TBST. The
membrane was then incubated with a mixture of the Chemiluminescent Substrate from
Bio-Rad for 5 min at room temperature without shaking and with the limited exposure to
light.. The signals were obtained by exposing the membranes to UltraCruz™
Autoradiography Film, Blue, sc-201697 (Santa Cruz) from 20 seconds to 10 minutes
depending on the intensity of the signals. The films were developed by putting them in
a Developer solution for no more than 5 seconds and a Fixer solution (5X stock
Developer, Cat#190-0984 and 5X stock Fixer, Cat#190-2485, Eastman Kodak Co.).
The resulting immunoblots were scanned and the images were analyzed by Image
Studio software from Licor.
2.9 Co-immunoprecipitations
HEK293 cells grown in 6-well plates were transfected with expression constructs
using Lipofectamine 2000.

24 hours post-transfection, the cells were lysed and

Immuno-precipitation was performed using the Protein G Immunoprecipitation Kit from
Invitrogen following the manufacturer’s protocol. The samples were then analyzed by
western blot analysis.
2.10 Protein expression in E. coli
Vectors designed for protein bacterial expression were transformed into BL21-A1
competent cells or BL21 cells from Invitrogen. The cells were plated on LB agar plate
for 18-20 hours at 37⁰C in an incubator. The LB agar plates contained an antibiotic as a
selection reagent. The next day, a colony from the plate was inoculated in 5-20 ml LB
medium with the appropriate antibiotic inside a sterile conical tube. The tube was
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incubated in a shaker at 37 °C and 200 rpm for 18-20 hours. The overnight culture was
transferred to a bigger flask containing LB medium with the appropriate antibiotic. Cells
were grown to an O.D of 0.6. Protein expression was induced using either IPTG
(Isopropyl β-D-1-thiogalactopyranoside) or IPTG and L-Arabinose. After induction , the
flasks were incubated in a shaker at 20⁰C and 200 rpm for 18-20 hours. The flasks were
then removed from the shaker and the cells were transferred to centrifuge tubes. The
cells were pelleted by centrifugation at 6000 rpmt 4 °C for 30 min . The supernatant or
the LB was discarded . The mass of the cells were recorded using a balance and cells
were stored at -80 °C .
2.11 Bacterial Cell lysis
Cells were resuspended in the appropriate lysis buffer.

Lysozyme and Halt-

Cocktail protease tablet inhibitors (ThermoFisher) were added to the resuspended cells
. The cells were then incubated on ice for 30 minutes . After incubation, the cells were
sonicated 3-4 times with 15 second pulses and 1 minute cooling cycles. The lysate was
centrifuged at 6000 rpm for 30 minutes. The supernatant and the pellet were separated
into different tubes. The supernatant, which contains the soluble protein fraction, was
then used for protein purification.
2.12 Recombinant Protein Purification
Recombinant proteins in this study either had a Histidine Tag or a GST tag at their
amino terminus.

These proteins were purified via affinity chromatography. Poly-

Histidine tags have an affinity for Nickel ions , so Pro-bond Nickel resin from invitogen
was used to purify proteins with a His-tag. GST has an affinity for glutathione so
Glutathione resin from Pierce was used to purify GST-tagged proteins.
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2.13 Buffer Exchange and Protein Concentrating
Purified protein fractions were subjected to buffer exchange to get rid of excess
Imidazole or glutathione. Desalting columns from Pierce Chemical Co. were used for
this process. The columns were washed 5 times with water and then 5 times with the
appropriate buffer for the protein. The purified protein fractions were added to the
column. The flow through was collected in a tube. Then, the protein was eluted by
washing the column with appropriate buffer for the protein. The elutions were collected
in 1 ml fractions. The fractions were analyzed for protein presence via Bradford Assay.
The samples that contained the protein were transferred to a Concentrator tube with
10,000 molecular weight cut-off(Millipore). The Concentrator tube was centrifuged at
5000 rpm until the volume of the protein solution was 1 ml . The pure protein sample
was then transferred into a microfuge tube and stored at -20⁰C .The concentration of the
protein was determined by the Lowry protein assay.
2.14 GST-Pull down Assay
The Pull-down Assay is an in vitro method used to determine physical interactions
between two or more proteins. The GST pull down Assay Kit was purchased from Piece
Thermo-scientific. Gluthione resin is added to a spin column and washed 5 times with
1:1 TBST Saline Buffer: lysis buffer Solution. The Bait protein (GST-tagged protein) is
then added to the Glutathione resin and incubated for 1 hour at 4 °C on a rocking
platform to allow the protein to bind. The protein bound resin is then washed 5 times
with 1:1 TBST saline buffer : lysis buffer solution to remove any non-specific bindings .
The prey protein is then added to the column and the column is incubated for 2 hours at
4 °C on a rocking platform to allow the prey protein to bind to the bait protein. After
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incubation, the protein complex is eluted with glutathione. The elution fraction is then
analyzed via western blot using the appropriate anitibodies to confirm the protein protein
interaction.
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CHAPTER 3
STRUCURAL CHARACTERIZATION OF FAM129B
3.1 Introduction
FAM129B is a 73 Kilobase gene located on Chromosome 9 in homo-sapiens
according the NCBI data.

The sequence is conserved in a variety of different

species as dog, chimpanzee, and rat. FAM129B expression patterns of different cell
lines analyzed by immunoblotting in our lab (data not shown) has shown that
FAM129B is highly expressed in tumor cell lines compared to non-cancer cell lines.
The expression seems to be also higher in metastatic cells lines compared to noninvasive cancer cell lines[22].
FAM129B belongs to a family of proteins of unknown function and structure. Not
much is known about FAM129B besides the fact that it is involved in cancer cell
invasion and suppression of apoptosis, which are the two of hall marks of Cancer.
Therefore, FAM129B exclusive expression in cancer cell lines and its involvement
in cancer cell progression highlight the use of FAM129B as a potential biomarker for
cancer and also a potential therapeutic target.
Knowing the structure of a protein can lead to implications about the function of
the protein. Also, knowing the structure will facilitate the design of a potent and
specific inhibitor for FAM129B using structure based drug design.
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The domain structure of FAM129B includes a Pleckstrin homology (PH) domain at
the N-terminus and a proline-rich domain that has 6 serine phosphorylation sites at
the C-terminus along with conserved DLG and ETGE motifs.
In this Chapter, I will show how I expressed and purified FAM129B and selenomethionine labelled FAM129B. I will also show some in-vitro characterization
analysis of FAM129B protein, such as circular dichroism and analytical gel filtration.
3.2 Materials and Methods
3.2.1 Expression of FAM129B.
FAM129B was previously cloned into the T7 Expresso Sumo vector from Lucigen Corp.
(Middleton, WI). The plasmid was then transformed into BL21.DE3 cells which are used
for expression of proteins in E. coli. The next day, a colony was picked (or an aliquot of
glycerol stock) was inoculated in 5 ml Luria Broth (LB) media with kanamycin ( 50
μg/ml) as a selection marker. The culture was grown overnight at 37°C with shaking at
200 rpm for no more than 18 hours. The 5 ml overnight culture was then added to the
large expression culture (500 ml) LB media and kanamycin. The cells were the grown at
37°C with shaking at 200 rpm until the optical density at 600 nm reached 0.5-0.6 which
occurs in 3 to 4 hours. Protein expression was induced with IPTG at a final
concentration of 0.5 mM. The cells were then left to grow at 20°C at with shaking at 200
rpm for 18 hours. The cells were then centrifuged at 4000xg for 30 minutes to remove
LB media. The cell mass was determined by an analytical balance and was either
processed rimmediately or stored at -80°C until needed.
3.2.2 Expression of Seleno-methionine labelled FAM129B (Sel-met FAM129B).
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Cultures were grown and processed with the same steps in the above section 3.2.1
until induction when the O.D. had reached 0.60. The cells were then pelleted by
centrifugation and gently mixed with methionine-free M10 minimal media (4g NH4Cl,12g
KH2PO4,24 g NaH2PO4 1g Magnesium sulfate ,0.05 g Ferrous sulfate in 500 ml of
distilled water). The cells were then resuspended with 500 ml of M10 media
supplemented with vitamin supplements, glucose, all amino acids expect for methionine
and 50 mg of seleno-methionine. The culture was incubated in the shaker at 37°C and
rotated 200 rpm until the O.D 600 reached 0.6. The culture was then induced with IPTG
added to a final concentration of 0.5 mM and the cultures were than incubated for 16-18
hours at 20°C shaking at 200 rpm. The cells were then pelleted by centrifugation.
3.2.4 Purification of FAM129B.
Cell pellets from the previous section were re-suspended in purification buffer (50 mM
Sodium Phosphate pH 8.0, 500 mM Nacl ) at a ratio of 5 ml/g of cell pellets. The cells
were gently suspended and protease inhibitor was added to the cell suspension. The
cells were incubated on ice for 30 min. The cells were lysed by sonication on ice at 30
second intervals with 3 minute cooling in-between 3 to 4 times. The cell lysate was then
centrifuged at 6000 rpm for 30 min at 4°C. The supernatant containing the soluble
protein including FAM129B was separated from the pellet by decanting. The
supernatant was then loaded on a column containing 2 ml of Nickel resin. This step is
the binding step where the His-FAM129B binds to the Nickel column and all other
bacterial proteins are – hopefully – eluted and collected, as the “flow through”. The
column was washed 3 times with 20 mM Imidazole in purification buffer. The
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recombinant protein was then eluted with 250 mM Imidazole in fifteen 1 ml fractions.
The pellet, supernatant, flow-through, the three washes, and the elutions were analyzed
by SDS page gel. The elutions were then pooled together and the protein was
concentrated down to a 1 ml volume using Millipore concentrators. The protein
concentration was determined by the Lowry Assay. For CD analysis and crystallization,
FAM129B was passed through a gel-filtration column (S-300) to further clean up any
impurities. The fractions were then concentrated and the protein concentration was
determined.
3.2.5. Gel filtration of FAM129B
1 ml of concentrated (20 mg/ml) of FAM129B was loaded onto the Bio-Rad gel filtration
system using 280 ml of S300 resin. The program was run at a flow rate of 1 mil/min
collecting a total of 320 ml of buffer (50 mM Tris pH 8.0, 200 mM NaCl ,1 mM DTT) in 4
ml fractions. A molecular weight standard from Bio-rad consisting of thyroglobulin (670
kDA), γ-globulin(158 kDa), ovalbumin (44 kDa), Myoglobin (17 kDa) and Vitamin B12
(1.35 kDa) was run on the same column and Log MW was plotted against the volume of
when the protein was eluted. The FAM129B oligomerization state was then determined
from the standard plot.
3.2.6 Circular Dichroism Analysis.
Purified FAM129B was buffer exchanged into 1 mM Sodium Phosphate buffer pH 7.5 at
a final concentration of 2.4 μM. The sample (400 μL) was loaded into a 0.1 cm cuvette
and inserted into the Circular Dichroism Spectrophotometer. Three separate spectra
were collected for the sample. The spectra were then accumulated using the JASCO
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C.D analysis software. The resultant spectrum was then analyzed using C.D proanalysis using the parameter Cotnin The alpha helices, beta-sheet, and random
secondary structures percentages were then calculated..
3.2.7 Crystallization Screening of FAM129B. Purified FAM129B in 50 mM Tris pH
8.0, 200 mM NaCl buffer at a final concentration of 10 mg/ml was screened for
crystallization conditions using the classic screen from Jenna Bioscience (JBS) and
classic suite screens from Qiagen. The hanging drop method was used for these
crystallization screens[23]. Briefly, 1 μL of purified protein was mixed with 1 μL of the
crystallization solution on siliconized microsope coverslip. The cover slip was inverted
placed over a well in a 24 well plate with each well containing a 0.5 ml of the different
crystallization solutions taking care that chamber was sealed tightly. The screens were
then checked under microscope at the time of set-up for any precipitation. The screens
were monitored every 3 days over a duration of 1 month. Any conditions that yielded
crystals were recorded and repeated for confirmation. The crystals were picked and
soaked with cryoprotectant (crystal condition with 20% ethylene glycol) and frozen in
liquid nitrogen. The crystals were sent to Argonne National lab Synchontron in Illinois for
data collection.
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3.3 Results
3.3.1 Purification of FAM129B In order to do In-vitro analysis of FAM129B, we first
set out to isolate the protein. Bacterial protein expression is a widely-established
method to isolate protein in vitro. FAM129B was cloned into a vector with a his-tag at
the amino terminus of the protein to enable the isolation of protein using affinity
chromatography with a Nickel resin bed as indicated in the methods. The expression.
and affinity purification gel in Figure 3.1A shows that FAM129B was successfully
isolated . The molecular weight of FAM129B is approximately 80 kDa from the gel.
FAM129B was gel-filtered by an S300 gel filtration column. The gel in Figure 3.1B
shows the final purity of FAM129B that was used in C.D analysis and crystallization.

A

B

Figure 3.1. Purification of FAM129B. (A) Recombinant FAM129B cloned into T7 SUMO
vector(lucigen) expressed in E.Coli. The protein was then purified by affinity purification.
Samples designated in the figure were ran on 12 % SDS-PAGE to assess the expression and
purification of recombinant FAM129B.(B) FAM129B was loaded onto an S300 gel filtration
column.The fractions that contained FAM129B were loaded onro SDS-PAGE gel with the
input to assess the purity of the fraction
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3.4.2 Analytical Gel filtration of FAM129B
We wanted to check if FAM129B exists in monomer, dimer, or trimer or any other
oligomeric state. Oligomeric state of the protein is associated with the function of
protein[24]. Gel filtration is a way of purifying proteins based on size so by comparing to
a molecular weight standard , the volume at where the protein elutes will give us an idea
about the protein oligomeric state. A sample of FAM129B (1 ml of 20 mg/ml) run on a
S300 gel filtration column eluted at 192 ml which corresponds to a molecular weight of
166 kDa, Therefore FAM129B exist as a dimer in solution.(Figure 3.2)

Figure 3.2. FAM129B exists as a dimer according to gel filtration Analysis. Recombinant
concentrated FAM129B protein was loaded onto S300 Gel filtration column. Fractions were
collected at a rate 1ml/min in 4 ml total fraction volume. Fractions that corresponded to the
peak were analyzed by SDS-PAGE gel to verify the existence of the protein.
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3.4.3 Circular Dichroism Analysis of FAM129B36
Since FAM129B is a new protein of unknown structure, we thought it would be
interesting to run a C.D analysis on the protein. Circular Dichroism Spectroscopy is a
method to determine the secondary structure of protein and the percent composition of
alpha-helices and beta sheets since they have distinct C.D spectra[25]. The C.D spectra
of FAM129B showed that the secondary structure composition is 37% alpha helices, 19
% beta sheets, 22% turns, and 22% undetermined. Figure 3.3 lists the exact values
obtained and shows the C.D spectrum of FAM129B.

Helices

37 %

Strands

19%

turns

22%

undetermined

22%

Figure 3.3. Circular Dichroism Spectra of Purified His-FAM129B 2.4μM in 1 mM Sodium
phosphate buffer was analyzed using a circular dichroism spectrophotometer. The resultant
CD spectra above showed the characteristic helix peak at 196 nm and the strand peak at
around 226 nm. The percentages of secondary structures are summarized in the table above.
The undermined structure is can be indicative of disordered regions.
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3.4.4 Crystallization Screens of FAM129B
Obtaining a Crystal is the rate limiting step for solving a structure of any protein by
X-ray

crystallography.

Usually,

structural

biologists

must

try

many

different

crystallization screens to obtain protein crystals[23]. FAM129B crystallization screens
yielded almost no crystals from 2 two different screens representing 500 different
conditions (Jenna Bioscience Crystallization Screen and the Qiagen Class Suite
Screen). Only one condition from the Qiagen classic screen yielded decent looking
crystals. The condition for crystallization is: 0.1M Na+ cacodylate, pH 6.5 , 30% MPD (2Methyl-2,4-pentanedio),0.2M Mg acetate shown in figure 3.4 The crystals were sent to
the LS-CAT synchrotron for analysis. However, the crystals obtained turned out to be
salt.

Figure 3.4. Crystallization Screening Results of Purified FAM129B. 10 mg/ml of purified
recombinant FAM129B in 50 mM Tris ,150 mM NaCl pH 7.5 was used in different
crystallization screens. The screens were set-up using the hanging-drop method. The
condition above 0.1M Na+ cacodylate pH 6.5 , 30% MPD , 0.2M Mg acetate. However, they
turned out be to be salt and not protein crystals.
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3.5 Discussion
Purification and Isolation of FAM129B from a bacterial expression system and the
subsequent analysis has yielded much information about the protein. First, FAM129B is
a soluble protein, which supports previous finding that FAM129B is predominantly a
cytosolic protein. Also the high solubility of FAM129B highlights the fact that FAM129B
might not be an integral part of cell membrane and can shuttle between and the cytosol
and the adherent junction as shown by Old et al[3].
The second observation is that FAM129B has been successfully purified at high
yields, which facilitates the study of the protein in subsequent studies in vitro such as
ITC, pull-down assays, and crystallization, which are experiments that require large
amounts of protein.
Gel filtration analysis of FAM129B has shown that FAM129B exists as a homo dimer
in solution in vitro. Oligomeric states of protein can affect the function of the protein[24].
FAM129B has six serine phosphorylation sites and a tyrosine phosphorylation close to
the carboxyl terminal of the protein. Since FAM129B was purified from bacteria that
have few kinases and do not phosphorylate mammalian proteins, we conclude that the
un-phosphorylated protein forms the dimer in this case. An interesting aim would be to
see how the different phosphorylation states affect the oligomeric state of the protein
and how does that affect FAM129B function as well[3].

Old et all has shown that

phosphorylation affects FAM129B localization to membrane. Therefore, if the oligomeric
state of the protein of FAM129B is affected by phosphorylation state, then dimerization
of FAM129B can also affect FAM129B localization to the membrane and the different
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functions that FAM129B exhibits in cancer cell, which include suppressing apoptosis
and promoting cancer invasion.
Circular Dichroism spectroscopy is used in the field of biochemistry and protein
structure to determine the secondary structure of protein. Around 40 % of FAM129B
consists of alpha helices and around 20% of protein composed of beta sheets. Around
22% of the protein seems to be unfolded or has no definite shape. We repeated the
analysis 2 times on 2 different batches of the purified protein and we got nearly identical
results. Around 22% remains mostly unfolded or undetermined. Secondary Structure
Prediction software tools online have shown that almost the entire carboxyl terminus of
FAM129B is disordered (Figure 3.5). This prediction agrees with our CD analysis of the
protein. Also, the domain structure of FAM129B shows that carboxyl terminal of
FAM129B is proline rich and has 7 phosphorylation sites which could be the reason for
the high percentage of the undetermined secondary structure and folding of the protein.
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Figure 3.5 . Disorder Predication Analysis. The protein sequence of
FAM129B was subjected to a disorder perdiction analysis. The results
predict that FAM129B has a highly disordered C-terminal region. The
disordered residues are labelled in red.

Source : Ishida, T and Kinoshita, K, PrDOS: prediction of disordered protein
regions from amino acid sequence., Nucleic Acids Res, 35, Web Server issue, 2007
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FAM129B Crystallization yielded no hits or good crystals. Crystallization of proteins is
dependent on many factors: the buffer of the protein, the crystallization condition, pH ,
protein concentration , temperature, and the folding of the protein[23] . Even though
FAM129B has been produced in high yields. is soluble and is stable in tris and
phosphate buffers, the crystallization of this protein was met with unfortunate results.
One reason that could be given for the low crystallization hits of FAM129B is the highly
disordered carboxyl terminal of protein. Future efforts should be made in dividing the
protein in a way that would facilitate crystal packing. Efforts should also be made in
crystallizing FAM129B with seleno-methionine residues. Since FAM129B does not have
any structurally homologous protein in the Protein Data Bank, molecular replacement
cannot be used to solve the structure . So to solve this problem, crystallization of selmet FAM129B will be necessary to determine the structure of the protein[26]. We have
successfully expressed and purified seleno-methaionine recombinant FAM129B as
shown Figure 3.6 Attempts to crystallize this protein have so far yielded no results.

Figure 3.6. Seleno-Methionine labelled FAM129B Protein
Purification gel
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CHAPTER 4
CHARACTERIZING THE INTERACTION BETWEEN FAM129B and KELCH-LIKE
ASSOCIATED PROTIEN 1,KEAP1
4.1 Introduction
FAM129B has been shown to suppress apoptosis in HeLa cells [4, 22]. Therefore,
we sought to identify possible interacting protein partners for FAM129B in the hopes to
better understand the mechanism by which FAM129B suppresses apoptosis.
Preliminary results in our lab from a Mass Spectrometry Analysis has identified KELCHlike associated protein 1, KEAP1 as a possible interacting partner[22] . The interaction
was confirmed by Immuno-precipitation of endogenous KEAP1 with GFP-FAM129B in
transfected HEK293 cells[22].

KELCH-like Associated Protein 1, also know known as KEAP1, is a 59 KDa zinc
protein. KEAP1 is a Cul3 based substrate recognition adaptor. KEAP1 can target
proteins for degradation through the Cul3 based ubiquitin ligase. The domain structure
of KEAP1 shows that KEAP1 has three distinct domains. The BTB domain at the amino
end of the protein is the site of KEAP1 homo-dimerization. Downstream of the BTB
domain is the IVR domain, which binds the CUL3 based Ubiquitin ligase. At the carboxyl
end of KEAP1 there are 6 KELCH repeats, which interact with proteins that contain an
ETGE motif, usually lead to degradation. The KECLH repeats have also been shown to
interact with the BH3 domain of BCL-2 .The KELCH domain of KEAP1 structure has
been solved[27]. The crystal structure shows that six copies of the KELCH repeats form
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a beta-sheet propeller where the target proteins are thought to bind into the center of
propeller shown in Figure 4.1[28]

Figure 4.1. Domain Structure of KELCH-Like associated Protein 1 (KEAP1).
•

Source: DOI: 10.2210/pdb1u6d/pdb

One of the most studied targets of KEAP1 is the antioxidant response protein NRF2.
Under normal conditions, KEAP1 binds to NRF2 through the KELCH repeats and the
ETGE motif respectively and targets NRF2 for degradation. However, upon oxidative
stress, KEAP1 -NRF2 complex is disrupted due to the reactive cysteines on KEAP1 and
NRF2 is released. NRF2 then translocates to the nucleus and activates the transcription
of the anti-oxidant responses protein. This process has been reported to be highly
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elevated in cancer cells to promote their survival. KEAP1 inactivation or down regulation
has also been reported in different types of cancer, including lung cancer[29].
IKKβ, also known as Inhibitor of nuclear factor Kappa B kinase, is also a target of
KEAP1 mediated degradation. IKKβ is highly elevated in cancer cells and is recognized
as an oncogenic kinase[30]. IKKβ also activates the NF-κB pathway. NF-κB or nuclear
factor kappa B is a transcription factor protein complex that activates transcription of
proteins that are involved in cellular growth and survival[10]. Several studies have
confirmed the direct interaction between IKKβ and KEAP1 and that KEAP1 downregulates IKKβ binding. These findings show that KEAP1 can down-regulate the NF-κB
pathway. This pathway has been reported to be elevated in many types of cancer and
NF-κB is considered an attractive drug target for many cancer therapeutics[16] .
The NF-κB pathway can be induced by TNFα. Since FAM129B suppresses the TNFα
apoptotic pathway in cancer cells, we hypothesized that FAM129B activates the NF-κB
pathway by competitively binding to KEAP1 and thus blocking the KEAP1 and IKKβ
interaction and thereby preventing the degradation of the kinase. The working model of
our hypothesis is illustrated in figure 4.2
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Figure 4.2. Working Model of Hypothesis. Overexpression of FAM129B in cancer leads to
FAM129B binding to KEAP1, thus preventing the latter from binding to IKKβ. IKKβ is then
protected from degradation which leads to an upregulation of NF-κB activation which
promotes the expression of anti-apoptotic proteins which ultimately leads to the suppression
of cell death.

But before further elucidating the mechanism, we have to confirm the interaction
between FAM129B and KEAP1. In this chapter I confirm the interaction between
KEAP1 and FAM129B through GST pull-down assays. I also identified the sites of
interaction between both proteins.
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4.2 Material and Methods
4.2.1 PCR and Cloning of KEAP1, KELCH REPEATS AND KEAP1ΔKELCH
pDEST15. Gateway Technology from Thermo-Fisher was used to efficiently clone
KEAP1 and the deletion constructs into pDEST15 plasmid, which has an aminoterminus GST tag. pcDNA KEAP1 vector was used as the template for the PCR
reaction.

The

primers

used

for

full

length

KEAP1

5’CACCATGCAGCCAGATCCCAGGCCTAGC,

,

Forward:
Reverse

:5’TCAACAGGTACAGTTCTGCTGGTCAATCTGCTTCCGGCA.
For the KELCH Repeats, Forward : 5’ CACCATGGCGCCCAAGGTGGGC. Reverse: 5’
TCAACAGGTACAGTTCTGCTGGTCAATCTGCTT . For KEAP1ΔKELCH , Forward: 5’
CACC ATGCAGCCAGATCCCAGG , Reverse: 5’CTACCGGCAGGGCATCACCTG
Following the PCR reaction, the inserts were then purified using quick PCR clean up kit
from Thermo-fisher. The PCR products were cloned into pENTR SD/TOPO plasmid
following the manufacturer’s protocol. The generated Entry clones were then incubated
with the destination vector pDEST15 following the manufacturer’s instructions. The
newly obtained clones were then verified by DNA sequencing by sending the samples
to Genscript , Picastaway , NJ.
4.2.2 Protein Expression of GST fused proteins
The GST fusion protein vectors were transformed into BL21-A1 expression strain
from Thermo-fisher. The next day, a colony was picked and inoculated into 5 ml LB
media with Ampicillin used as a selection marker. The culture was grown for 18 hours at
37°C and shaking at 200 rpm. The overnight culture was then transferred to a 500 ml
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LB media with ampicillin. The expression culture was left to grow at 37°C and shaking at
200 rpm until the Absorbance at 600 nm reached 0.5. Protein expression was then
induced by adding both IPTG and L-arabinose at a final concentration of 0.5 mM and
0.2 % w/v respectively. Following Induction, the cells were left to grow overnight at 25°C
and shaking at 200 rpm for no more than 16 to 18 hours. The cells were then pelleted
by centrifugation and the mass of cells was determined. The cell pellet was either used
directly for purification or stored at -80°C until needed.
4.2.3 Purification of GST fused proteins.
GST fusion proteins were purified using Glutathione resin (2 mL). The cells from the
previous section were resuspended in purification buffer (50 mM Tris pH 8.0, 150 mM
NaCl) at a 5 ml of buffer / 1 g cells ratio. Protease Inhibitors were added and the cells
were incubated on ice for 30 min. The cells were then lysed by sonication for at 30 sec
intervals with 1 min cooling interval in between 3 to 4 times. The cell lysate was pelleted
by centrifugation at maximum speed for 30 minutes. The supernatant was then loaded
on to the Glutathione column at a flow rate 20 drops/ min. The GST protein now bound
to the column was washed three times with purification buffer. The protein was eluted
with buffer containing reduced glutathione (250 mM) , 50 mM Tris , 150 mM NaCl at pH
8.0. The elution volume was collected in ten 1 ml fractions. The samples were the
analyzed by SDS-PAGE gel to assess purity of protein. The protein was concentrated
down to 1-2 ml volume using Millipore Concentrators and the protein concentration was
determined by the Lowry method.
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4.2.4 GST Pulldown Assays
Approximately 150-250 μg of purified GST tagged recombinant proteins were incubated
with 25 μg of GST resin for 1 hour at 4⁰C. The GST resin with boiund protein was
washed and then 150 μg - 250 μg of purified His-FAM129B was added. The proteins
were incubated for 2 hours at 4⁰C . The protein complexes were eluted and the samples
were analyzed using Western blots with His tag and GST tag antibodies.
4.2.5 Immuno-precipitation Experiments
HEK293 cells were grown in a 6 well plate until they were 60-80% confluent . The cells
were then transfected with 2.5 μg

of plasmid using Lipofectamine 2000 (Life

technologies) . 24 hours post- transfection, the cells were lysed and an
immunoprecipitation was performed with a GFP antibody using the G-protein
Immunoprecipitation kit (Life Technologies) according to the manufacturer’s protocol .
The samples were then analyzed via Western Blot using KEAP1 and GFP antibodies (
Cell Signaling).
4.2.6 Immuno-Flourescent Microscopy
HeLa were plated on glass cover slips and grown to 60-80% confluency.The cells were
serum starved overnight and then treated with TNFα (10 ng/ml) for 30 min. The media
was the aspirated from the well. The cells on the coverslips were then washed with PBS
(Phosphate buffered Saline) 3 times. The cells were then fixed with 10% formalin and
permeabilized with 0.2% Triton-X. Next, the cells were blocked with 1% BSA in PBS for
1 hour. After blocking, the cells were washed 3 times with PBS. The cells were
incubated with antibodies against FAM129B and KEAP1 (1:50) in blocking buffer for 2
hours. After washing the cells 3 times with PBS, the cells were incubated with Alexa
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flour 594 Goat anti-Rabbit and 488 Goat anti-mouse for 1 hour. The cells were then
washed with PBS. After that, the coverslips were the mounted on clean microscope
slides using Prolong Gold Anti-Fade mountant with DAPI (Life Technologies, P36931).
The microscope slides were then stored in the dark at 4°C overnight to allow the slides
to dry. The cells were analyzed using a fluorescent microscope Nikon E800.
4.3 Results
4.3.1 Cloning of KEAP1 and the Deletion Contracts in pDEST15 vector.
To perform In-vitro GST pulldown, KEAP1 had to be cloned into a GST tagged
plasmid. We then divided KEAP1 into two parts so we can examine which domain
specifically binds FAM129B. These two parts are the KELCH repeats (GST-KELCH)
and KEAP1 without KELCH repeats (GST-KEAP1ΔKELCH). The PCR agarose gels of
the full length KEAP1 and the truncated constructs show that the PCR reaction was
successful (Figure 4.3) The inserts were cloned into the entry clone and then further into
the destination vector pDEST15. The resulting clones were confirmed by sequencing to
check for two criteria: 1) that the sequence was correct. 2) KEAP1 and the deletion
constructs inserts were in frame and properly fused with the GST tag at the amino
terminus. The sequencing results showed that both criteria were met for all 3 clones.
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Figure 4.3. PCR results for the amplification of KEAP1 and the corresponding Deletion
Constructs. 5 μL of purified PCR product was mixed with 1 μL of 6X loading ( New
England’s Biolab). The samples were resolved on 0.8% agarose gel. Images were taken
using UVP gel imager
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4.3.2 Expression and Purification of GST-KEAP1, GST KELCH Repeats, and GSTKEAP1-ΔKELCH
Expression and Purification of GST-KEAP1 was successful. The protein was soluble
and was purified as indicated in Figure 4.4. The gel also shows that the molecular
weight of GST-KEAP1 is approximately 80 kDa. To further confirm our results, the
samples were subjected to Western Blot analysis using both GST tag antibody and
KEAP1 antibody. The resulting Immuno-blot showed that KEAP1 was indeed expressed
and purified. The purification of both the deletion constructs: GST-KELCH and GSTKEAP1ΔKELCH was also successful as indicated in Figure 4.4(D&E)
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A

D

C

E

Figure 4.4. Purification of GST tagged KEAP1, GST-KELCH, and GST-KEAP1ΔKELCH.
(A) SDS-PAGE gel of the purification of full length GST-KEAP1 using GST affinity
Chromatography. (B,C) Alternatively, samples from (A) have been analyzed by Western blot
using antibodies against GST and KEAP1. (D) SDS-PAGE gel of the GST-KELCH repeats
purification. (E) SDS-PAGE gel of GST-KEAP1ΔKELCH purification.

0
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4.3.3 FAM129B interacts directly with KEAP1 in vivo and in vitro.
FAM129B has an ETGE motif at the carboxyl terminus, which potentially interacts with
the KELCH like protein 1 (KEAP1). KEAP1 has also been shown to negatively regulate
the NF-KB pathway[28]. So we aimed to see whether FAM129B and KEAP1 interact.
Recombinant FAM129B with a GFP tag at the C-terminal and variable of deletion
constructs were transfected into HEK293 cells as indicated in figure 4.5A. 24 hours post
transfection, the cells were lysed and subjected to an Immuno-precipitation using
antibodies against GFP. The samples were analyzed by western blotting using
antibodies against FAM129B and KEAP1. The results show that FAM129B forms a
complex with KEAP1. The ETGE motif of FAM129B is the site of interaction between of
FAM129B and KEAP1, since FAM129B-ETAA-GFP , which has a mutated ETGE motif,
disrupted the interaction (Figure 4.5B). Phosphorylation of the serine at residue 683
does not seem to have an effect on the interaction between FAM129B and KEAP1.
FAM129B-S683D-GFP and FAM129B-S683A-GFP were both able to pull-down KEAP1
(Figure 4.5B). We then posed the question whether this interaction is direct. We
performed a GST pull-down assay using purified recombinant KEAP1 with a GST tag
and purified recombinant His-FAM129B. We also made deletion constructs of KEAP1:
the KELCH domain by itself, and the full length KEAP1 without the KELCH domain.
Both of these constructs were purified with a GST tag on their amino end and used in
the GST pull-down assay with FAM129B. The resultant western blots showed that
FAM129B and KEAP1 interact directly in vitro and that the KELCH domain is the site of
interaction between KEAP1 and FAM129B. (Figure 4.6).
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B
A

Figure 4.5. FAM129B interacts with KEAP1 through its ETGE motif. (A) Constructs used
in the immunoprecipitation experiment in panel B. (B) HEK293 cells were transfected with the
constructs in (A). 24 hours post-transfection, the cells were lysed and subjected to an
immunoprecipitation using anti-GFP antibodies. The samples were then analyzed by an
immuno-blot using antibodies against GFP and KEAP1. (Song Chen, unpublished)

0
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A

C

D

E

Figure 4.6. FAM129B interacts with KEAP1 directly through the KECLH repeats of
KEAP1. (A) Domian structures of FAM129B and KEAP1. (B,C,D,E) . Purfied GST-KEAP1,
GST-KELCH, or GST-KEAP1ΔKELCH were incubated with GST resin to immobilize the GST
tagged proteins. The resin was then washed and Recombinant His-FAM129B was added to
the resin and incubated at 4°C with gentle shaking for 2 hours. The protein complexes were
then eluted and analyzed by Western blot using GST antibodies and his-tag antibodies.

0
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4.3.4. Localization of FAM129B and KEAP1 upon TNFα treatment.
KEAP1 is primarily a cytosolic protein [31] while studies in our lab have shown that
FAM129B is normally associated with the adherent junction. Since we hypothesize that
FAM129B and KEAP1 interact to suppress TNFα induced apoptosis, we investigated
the localization of FAM129B upon TNFα treatment, Indeed, immunofluorescent results
show that FAM129B is mainly localized to the plasma membrane in the control where
KEAP1 is dispersed throughout the cytoplasm. However, upon treating these HeLa cells
with TNFα for 30 min, FAM129B is now no longer at the plasma membrane and is
dispersed throughout the cytosol in a similar manner as KEAP1.

Figure 4.7 FAM129B and KEAP1 seem to co-localize upon TNFα treatment in
HeLa Cells. HeLa cells grown on glass coverslips were incubated with TNFα (10
ng/ml) for 30 min. The cells were analyzed by Immunoflouresent Microscopy using
antibodies FAM129B and KEAP1.
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4.4 Discussion
The transactivation of NF-Kb is one of the many pathways regulated by KEAP1. KEAP1
has been shown to promote the TNFα apoptotic pathway by regulating IKKβ levels in
the cell. IKKβ, binds to KEAP1 through its ETGE motif to KEAP1 .Then KEAP1 binds to
cul3 through its IVR domain. The cul3 protein then recruits the E3 Ubiquitin ligase and
thus IKKβ gets targeted for proteasome degradation. This process, which prevents
activation of NF-KB and the subsequent transcription of anti-apoptotic proteins,
promotes [9, 28, 31, 32]. We showed that FAM129B and KEAP1 interact directly
through

the

ETGE

motif

and

the

KELCH

domain

respectively

by

ex-vivo

immunoprecipitations and in-vitro GST pull-down assays. It has been also reported that
IKKβ binds to KEAP1 at the KELCH domain of KEAP1 [6], which implies that FAM129B
and IKKβ may competitively bind to KEAP1.TNFα also might be play a role in the
interaction between FAM129B and KEAP1. Immunofluorescent results showed that
FAM129B and KEAP1 co-localize in the cytosol upon TNFα treatment compared to the
control where FAM129B is predominantly located at the adherent junction and KEAP1 is
dispersed throughout the cytosol. This observation further supports the idea that
interaction of KEAP1 and FAM129B is the reason why FAM129B suppresses the TNFα
apoptotic pathway in HeLa cells. KEAP1 has been shown to promote apoptosis by
targeting IKKβ for degradation [28]. When HeLa cells were treated with TNFα,
FAM129B, which is normally localized at the membrane, moves to the cytosol where
KEAP1 is present. FAM129B then interacts with KEAP1, thus disrupting the interaction
between IKKβ and KEAP1. IKKβ is not targeted for degradation and activates the NF-
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κB pathway and apoptosis is suppressed . However, further experiments need to be
done to validate this conclusion

50

CHAPTER 5
THE ROLE OF FAM129B IN CANCER CELL INVASION
5.1 Introduction
Suppression of apoptosis is a prerequisite for cancer cell invasion [12]. Preliminary
data in our lab has shown that in exponentially growing HeLa cells, FAM129B was
cytosolic but was translocated to the membrane when cells came in contact with each
other[4] . Also knock-down of FAM129B expression reduced cancer cell movement
through a matri-gel assay[22]. These findings suggest that FAM129B promotes cancer
cell motility.
Metastasis is the process where cancer cells acquire genetic and biochemical changes,
which allows the tumor cells to leave the primary tumor site and form colonies at a
secondary site. Metastatic cells are the cause of 90% of cancer deaths[17]. Cancer cell
invasion is a complex process where the biochemical and genetic make-up is still poorly
understood.
Research into metastasis has revealed that adherent junction proteins are among the
most altered proteins in metastatic cells. One of these proteins that is widely studied is
E-Cadherin, a protein that is part of the classic cadherin family protein that mediate cellcell interaction and helps organize the adherent junction. E-Cadherin forms a complex
with β-catenin which is involved in regulating the cytoskeleton dynamics and modulating
signal transduction pathways[33]. Forced expression of E-Cadherin in cultured cancer
cells and a transgenic mice model impairs invasive and metastatic phenotypes whereas
loss or interference in E-Cadherin function enhances both capabilities[12]. Thus, E-
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cadherin acts as a suppressor of metastasis in epithelial cancers[12]. A process called
the “Cadherin Switch” is a widely observed process in many metastatic or malignant
cancers. Cadherin switching in cancers means the replacement of the E-Cadherin,
which is an epithelial marker and a main component of the adherent junctions that keep
the cells connected to one another, to N-Cadherin, which is a type of Cadherin that has
a shorter extracellular region than E-cadherin and is regarded as a mesenchymal
marker that promotes cell mobility. Invasive cell lines expression profiles show that NCadherin is highly expressed in these cell lines while E-Cadherin expression is
negligible, an observation that supports the Cadherin Switching process[34, 35].
The epithelial to mesenchymal transition is a normal cellular process that is critical for
morphogenesis and homeostasis of solid tissues. In cancer, EMT is highly upregulated.
Malignant epithelial cells undergoing EMT acquire properties that facilitate metastatic
spread. EMT also renders cancer cells resistant to different types of therapies, often by
reducing apoptotic sensitivity [18]. Also, metastatic cancer cell lines have elevated
expression of mesenchymal markers such as vimentin and negligible expression of
epithelial markers such as E-Cadherin[36]. EMT is induced by chemokines such as
Transforming Growth Factor Beta (TGFβ)[37]. The adherent junctions that connect the
cells to one other degrade as proteins that are associated with epithelial morphology,
such as E-Cadherin, occludens, and claudins are degraded. At the same time, proteins
responsible for mesenchymal morphology, such as N-Cadherin, SNAIL, and vimentin
are upregulated. Matrix Metalloproteinases (MMPs) are also upregulated and degrade
the basement membrane and extracellular matrix (ECM) to promote the detachment of
the mesenchymal cells[38].

52

In this chapter, we reveal that FAM129B expression is upregulated by the epithelial to
mesenchymal transition. We also show that FAM129B phosphorylation by MAP kinase
translocates the protein to membrane while inhibiting MAP kinase removes FAM129B
from the membrane. These findings confirm the role of FAM129B in cancer cell
invasion.
5.2 Materials and Methods
5.2.1 Antibodies and Reagents:
Antibodies directed against FAM129B , N-cadherin, and Vimentin were purchased from
Cell signaling Technology. GAPDH antibodies and N-cadherin siRNA were from Santa
Cruz Biotechnology. TGFβ was purchased from Genscript. EGF , U1206 , and PD10356
were from Sigma.
5.2.3 MAPK Kinase Pathway Activation:
HeLa cells incubated in serum-free DMEM media for 18-20 hours were treated with
EGF (10 nM) or PMA (10 μM) for 30 minutes. FAM129B localization was then analyzed
by immuno-fluorescence microscopy. Alternatively, cells treated with EGF and PMA for
30 minutes were then treated with specific MEK inhibitors U1026(10 μM) and PD10356
(10 μM) for an hour prior to FAM129B localization analysis.
5.2.4 Epithelial to Mesenchymal transition (EMT) induction.
A549 cells growing in RPMI media were first serum-starved for 18-20 hours. EMT was
induced by TGFβ (10 ng/ml) treatment for 48 hours,. The cells were then lysed and the
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lysate was analyzed by Immuno-blotting using antibodies for FAM129B, GAPDH
(loading control ) and vimentin (mesenchymal marker) to check for transition success.
5.2.5 Immuno-fluorescence Microscopy:
HeLa cells were seeded on cover slips in a 6-well plate and serum starved overnight.
The cells were washed three times with PBS, fixated with 10% formalin, and
permeabilized with 0.2% Triton-X.

After blocking with 1% BSA in PBS for 1 hour, the

cells were washed 3X with PBS and then incubated with either FAM129B rabbit with or
without either N-cadherin antibodies (1:100 dilution) for 2 hours. The cover-slips were
washed with PBS and incubated for 1 hour with either Alexa flour 488 Goat anti-Rabbit
and 594 Goat anti-mouse. After washing with PBS, the coverslips were then mounted
on microscope slides using Prolong Gold Anti-Fade mountant with DAPI (Life
technologies, P36931). The microscope slides were then dried in the dark at 4°C
overnight. The cells were then visualized using a Nikon E8000 fluorescent microscope.

5.3 Results
5.3.1 Immunofluorescent data show that FAM129B localizes to the adherent
junctions where it co-localizes with N-Cadherin
Preliminary data in our lab has shown that FAM129B localizes at the cell membrane
when cells are in contact with each other. We wanted to check whether FAM129B is
associated with any of the adherent junction proteins such N-cadherin. To test this, colocalization experiments between FAM129B and N-cadherin using immunofluorescence
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were conducted. The results showed that FAM129B localizes to the membrane in
confluent HeLa cells while it is dispersed throughout the cytososl in non-confluent
cells(Figure 5.1A). Figure 5.1 B shows that N-cadherin is also at the membrane in
confluent cells indicating that FAM129B and N-cadherin co-localize at the membrane in
confluent HeLa cells.

A

B

Figure 5.1. FAM129B co-localizes with N-Cadherin in Confluent HeLa cells. (A)
Immunofluorescent images of endogenous FAM129B (green) in exponentially growing HeLa
cells and in confluent HeLa cells. (B) HeLa cells grown on glass cover slips were stained for
FAM129B (green) and N-Cadherin ( red). Images were taken using an Nikon E800
fluorescent microscope
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5.3.2 Knockdown of N-cadherin expression displaces FAM129B from the
membrane in confluent HeLa cells.
Since FAM129B co-localizes with N-cadherin in HeLa cells, we decided to test
whether N-cadherin knockdown has any effect on FAM129B localization. To test this
hypothesis, N-cadherin expression was knocked-down using siRNA technology and
cells were analyzed using Immuno-fluorescent microscopy. The results show that in the
control cells, FAM129B and N-cadherin co-localize at the membrane. However, in the
transfected cells, N-cadherin expression is completely knocked down and that
FAM129B is dispersed throughout the cytoplasm in these cells.(Figure 5.2).
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Figure 5.2. Knockdown of N-Cadherin expression in HeLa seems to inhibit FAM129B
localization to the membrane. HeLa cells grown on glass cover slips were transfected with
siRNA N-cadherin. 48 hr post transfection, the cells were analyzed by Immunofluorescent
microscopy using antibodies against FAM129B (green) and N-Cadherin (red).

5.3.2 MAP Kinase phosphorylation of FAM129B localizes FAM129B to the plasma
membrane
Old et al has reported that FAM129B is localized to the plasma membrane in
melanoma cells upon treatment with MAP kinase inhibitors[3]. We decided to
investigate whether phosphorylation of FAM129B has any effect on localization of
FAM129B in confluent HeLa cells. Immunofluorescent results showed that contrary
to the literature, FAM129B was localized to the membrane upon treatment with EGF
which activates MAP kinase. Thus, phosphorylation of FAM129B localizes
FAM129B to the membrane while treatment with two different MEK inhibitors,
PD98059 and U1026, removes FAM129B completely from the membrane.
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FAM129B was also localized to the membrane in PMA treated cells where MAP
Kinase is indirectly activated while treatment of these cells with MEK inhibitor U1026
translocated FAM129B back to the cytosol. (Figure 5.4)

Figure 5.3. FAM129B is phosphorylated by MAP Kinase. HeLa cells were treated with with
EGF, U1026, or EGF and U1026. The cells were then lysed and analyzed by Western blot.
The shift in the FAM129B indicates phosphorylation of FAM129B by MAP Kinase. (Song
Chen, unpublished )
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Figure 5.4. FAM129B phosphorylation by MAP kinase translocate FAM129B to the
membrane. HeLa cells grown on glass cover slips were treated with different activators and
inhibitors indicated in the figure The cells were then fixed and analyzed by immunofluorescent
microscopy.
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5.3.3 FAM129B expression is upregulated when EMT is induced in A549 cells
FAM129B is expressed at high levels in cell lines when vimentin was
upregulated[22]. Vimentin is a mesenchymal marker[38] so we wanted to see
whether Epithelial to Mesenchymal transition affects FAM129B expression.
Treatment of A549 cells with TGFβ1 for 48 hours shows that EMT was induced
successfully since vimentin was expressed. The resulting western blot also showed
that FAM129B expression increased upon EMT induction in A549 cells (Figure 5.5).

Figure 5.5. FAM129B expression level increases when EMT is induced by TGFβ . A549
cells ( lung cancer cells ) were grown in 60 mm dish in RPMI and 10% FBS. When the cells
were 80% confluent , The media was replaced with 1 % RPMI medium and EMT was
induced with TGFβ ( 20 ng ) for 48 hours. The cells were then lysed and analyzed by western
blotting. Vimentin was used as mesenchymal marker. GAPDH was used as a loading control
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5.4 Discussion
FAM129B was first identified in the literature as an adherent junction associated
protein[4].

Results in our lab have consistently shown that FAM129B might be

involved in cancer cell invasion. FAM129B is highly expressed in metastatic cell
lines compared to non-invasive cell lines. Furthermore, knockdown of FAM129B in
invasive breast cancer cell line MDA-MB-231 decreased cancer cell motility in vitro
[22].
Consistent with previous findings, FAM129B is localized to the cell membrane
when HeLa cells are in contact with each other. This led to the hypothesis that
FAM129B might interact with adherent junction proteins at the membrane. Colocalization experiments showed that FAM129B is localized at the adherent junction
with N-cadherin. FAM129B is displaced from the cell membrane when N-cadherin
expression is knocked-down as a result of disruption of the junction. These results
confirm that FAM129B is associated with the adherent junction. Another possibility
is that FAM129B interacts with phospholipids at the membrane via its Pleckstrin
homology (PH domain), which has yet to be investigated. The association of
FAM129B with the membrane suggests that the protein could be involved in various
cellular signaling cascades or might play the role in regulating the adherent junction
dynamics, which is another possible mechanism for the role of FAM129B in cancer
cell invasion
As mentioned several times previously, FAM129B has several phosphorylation
sites at its carboxyl-terminus. Old et al also mentioned in his study that
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phosphorylation of FAM129B promoted melanoma cell invasion in vitro and also
affected FAM129B localization to the membrane. We decided to test this result in
HeLa cells. Activation of MAP kinase by both EGF and PMA has caused FAM129B
to localize to the membrane in HeLa cells. While treatment with MEK inhibitors for
both the EGF and PMA treated cells re-located FAM129B into the cytosol, indicating
that in both treatments, the localization effect is specifically due to MAP kinase.
MAP kinase activation has been reported to be associated with cellular migration.
Treatment of cells with EGF and TGFβ together also promotes the epithelial to
mesenchymal (EMT) activation at a faster rate than TGFβ alone in cell culture [39].
Therefore, FAM129B phosphorylation could play a major role in cancer cell invasion
by accelerating EMT induction.
The epithelial to mesenchymal transition is a process where cells undergo
biochemical and morphological changes that enables cells to move from one place
to another. EMT is a naturally occurring process during development and wound
healing and is tightly regulated. In cancer cells, several studies have reported that
EMT is upregulated in cancer cells and helps tumors acquire metastatic
properties[36]. FAM129B is upregulated in cell lines where vimentin was
expressed[22] so we investigated if FAM129B might be essential for EMT. Induction
of EMT in A549 cells, a cell line that is widely used for EMT studies[40], increased
FAM129B compared to controls. This finding shows that FAM129B expression is
induced by TGFβ and that FAM129B may play a role in the epithelial to
mesenchymal transition. My hypothesis is that FAM129B promotes cancer cell
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mobility through its association with the adherent junction. Still, further experiments
need to be done to validate this hypothesis.
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FAM129B/Minerva, a protein implicated in melanoma cell invasion, has been shown to
suppress TNFα induced apoptosis in cancer cells (Song, Evans & Evans (2010), JBC
286, 10201-09), thus contributing to the survival of metastatic cells. KEAP1, a substrate
recognition molecule for the CUL3 E3 ubiquitin ligase, plays a central role in the
activation of the TNFα pathway. We wish to test the hypothesis that the up-regulation of
FAM129B in cancer cells suppresses apoptosis by sequestering KEAP1, thus
preventing its participation in the apoptotic pathway. The first step is to demonstrate that
FAM129B and KEAP1 form a complex. We have cloned and expressed the proteins in
E. coli and purified both to homogeneity. Pull downs and immunoprecipitation clearly
showed that the two proteins form a high affinity, stoichiometric complex. Using
individually cloned domains, as well as mutations of the ETGE motif in FAM129B, the
binding sites on each protein have been located. The proline rich region of FAM129B
was shown elsewhere (Old et. al. (2009) Mol Cell.34,115) to be phosphorylated by MAP

69

kinase (Erk1/2) at four sites. The effect of MAP kinase, which is upregulated in cancer
cells, and PKC phosphorylation on the stability and formation of the complex has also
been investigated.
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